News

According to the company, the Hemopurifier is a medical device that assists the immune response in combating infectious disease through real-time therapeutic filtration of infectious viruses and immunosuppressive

Under the agreement, ParkwayHealth will become the Asian affiliate in The Global Prevention Network, a select group of healthcare institutions with recognized preventive and executive health programs. US

The Phase IIa trial is a multicenter, randomized, double-blind, placebo-controlled study primarily investigating the safety and tolerability of EHT 0202 in approximately 150 patients with Alzheimer’s disease. The

If approved, Arzerra (ofatumumab) would be indicated for the treatment of patients with chronic lymphocytic leukemia who have previously failed, or are inappropriate for, standard therapies. The marketing

Hawaii Biotech is developing a West Nile recombinant sub-unit vaccine to induce protective immunity in recipients of the vaccine. The results demonstrated a favorable safety profile in 24

Clarus Ventures led the syndicate, which includes the founding investor, MVM Life Science Partners, and the Novartis Option Fund. All three investors contributed equally. Michael Steinmetz for Clarus

ARX424 was created by Ambrx through the application of its proprietary protein optimization technology, ReCODE. This second collaboration between the two companies follows a previous agreement announced in

The study evaluated symptomatic progress of US patients involved in the company’s two initial 2003 Phase I-II studies of NX-1207. Patients treated with NX-1207 were followed-up on an

For the year ended December 31, 2008, the company’s cash, cash equivalents, investments and settlement rights associated with certain auction rate securities totaled $215.0 million. Revenues for the